keyword
MENU ▼
Read by QxMD icon Read
search

Primary effusion lymphoma

keyword
https://www.readbyqxmd.com/read/28506687/human-immunodeficiency-virus-hiv-and-epstein-barr-virus-ebv-related-lymphomas-pathology-view-point
#1
REVIEW
Ebru Linke-Serinsöz, Falko Fend, Leticia Quintanilla-Martinez
The contribution of Epstein Barr virus (EBV) and Kaposi sarcoma herpes virus (KSHV) to the development of specific types of malignant lymphomas occurring in the human immunodeficiency virus (HIV) setting has been extensively studied since the beginning of the HIV epidemic 35 years ago. The introduction of highly active antiretroviral therapies (HAART) in 1996 has changed dramatically the incidence of HIV-related malignancies. Nevertheless, malignant lymphomas continue to be the major group of malignances observed in HIV infected individuals, and the most common cause of cancer related-deaths...
April 7, 2017: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/28504647/identification-of-a-nucleoside-analog-active-against-adenosine-kinase-expressing-plasma-cell-malignancies
#2
Utthara Nayar, Jouliana Sadek, Jonathan Reichel, Denise Hernandez-Hopkins, Gunkut Akar, Peter J Barelli, Michelle A Sahai, Hufeng Zhou, Jennifer Totonchy, David Jayabalan, Ruben Niesvizky, Ilaria Guasparri, Duane Hassane, Yifang Liu, Shizuko Sei, Robert H Shoemaker, J David Warren, Olivier Elemento, Kenneth M Kaye, Ethel Cesarman
Primary effusion lymphoma (PEL) is a largely incurable malignancy of B cell origin with plasmacytic differentiation. Here, we report the identification of a highly effective inhibitor of PEL. This compound, 6-ethylthioinosine (6-ETI), is a nucleoside analog with toxicity to PEL in vitro and in vivo, but not to other lymphoma cell lines tested. We developed and performed resistome analysis, an unbiased approach based on RNA sequencing of resistant subclones, to discover the molecular mechanisms of sensitivity...
May 15, 2017: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28502522/human-herpesvirus-8-related-diseases-histopathologic-diagnosis-and-disease-mechanisms
#3
REVIEW
Matthew Auten, Annette S Kim, Kyle T Bradley, Flavia G Rosado
The emergence of HIV/AIDS more than three decades ago led to an increased incidence of diseases caused by HHV8 co-infection, particularly Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Over time, the development of highly effective AIDS therapies has resulted in a decreased incidence of HHV8-associated entities, which are now more commonly found in patients with undiagnosed and/or untreated AIDS. Due to their rarity, some of these diseases may be difficult to recognize without appropriate clinical information...
April 6, 2017: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/28481873/restoring-pu-1-induces-apoptosis-and-modulates-viral-transactivation-via-interferon-stimulated-genes-in-primary-effusion-lymphoma
#4
H Goto, R Kariya, E Kudo, Y Okuno, K Ueda, H Katano, S Okada
Primary effusion lymphoma (PEL), which is an aggressive subgroup of B-cell lymphoma associated with Kaposi sarcoma-associated herpes virus/human herpes virus-8, is refractory to the standard treatment, and exhibits a poor survival. Although PU.1 is downregulated in PEL, the potential role of its reduction remains to be elucidated. In this investigation, we analyzed the DNA methylation of PU.1 cis-regulatory elements in PEL and the effect of restoring PU.1 on PEL cells. The mRNA level of PU.1 was downregulated in PEL cells...
May 8, 2017: Oncogene
https://www.readbyqxmd.com/read/28468596/multiple-viral-infections-in-primary-effusion-lymphoma-a-model-of-viral-cooperation-in-lymphomagenesis
#5
Annunziata Gloghini, Chiara C Volpi, Ambra V Gualeni, Riccardo Dolcetti, Italia Bongarzone, Paolo De Paoli, Antonino Carbone
Primary effusion lymphoma (PEL) is a rare B-cell lymphoid neoplasm mainly associated with HIV infection, presenting as pleural, peritoneal, and pericardial effusions. A defining property of PEL is its consistent association with Kaposi sarcoma associated herpesvirus (KSHV) infection, and, in most cases, Epstein Barr virus (EBV) co-infection. On these grounds, a review of the literature related to viral cooperation and lymphomagenesis can help to understand the complex interplay between KSHV and EBV in PEL pathogenesis...
May 4, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28459883/nlrx1-negatively-modulates-type-i-ifn-to-facilitate-kshv-reactivation-from-latency
#6
Zhe Ma, Sharon E Hopcraft, Fan Yang, Alex Petrucelli, Haitao Guo, Jenny P-Y Ting, Dirk P Dittmer, Blossom Damania
Kaposi's sarcoma-associated herpesvirus (KSHV) is a herpesvirus that is linked to Kaposi's sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). KSHV establishes persistent latent infection in the human host. KSHV undergoes periods of spontaneous reactivation where it can enter the lytic replication phase of its lifecycle. During KSHV reactivation, host innate immune responses are activated to restrict viral replication. Here, we report that NLRX1, a negative regulator of the type I interferon response, is important for optimal KSHV reactivation from latency...
May 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/28459467/ribonucleotide-reductase-represents-a-novel-therapeutic-target-in-primary-effusion-lymphoma
#7
L Dai, Z Lin, J Qiao, Y Chen, E K Flemington, Z Qin
Primary effusion lymphoma (PEL) is a highly aggressive B-cell malignancy that is closely associated with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus. PEL prognosis is poor and patients barely survive >6 months even following active chemotherapy interventions. There is therefore an urgent need to discover more effective targets for PEL management. We recently found that the ribonucleotide reductase (RR) subunit M2 is potentially regulated by the key oncogenic hepatocyte growth factor/c-MET pathway in PEL...
May 1, 2017: Oncogene
https://www.readbyqxmd.com/read/28455950/rhadinoviral-interferon-regulatory-factor-homologues
#8
Sandra Koch, Thomas F Schulz
Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8 (HHV8) is a gammaherpesvirus and the etiological agent of Kaposi's sarcoma, primary effusion lymphoma and multicentric Castleman disease. The KSHV genome contains genes for a unique group of proteins with homology to cellular interferon regulatory factors, termed viral interferon regulatory factors (vIRFs). This review will give an overview over the oncogenic, antiapoptotic and immunomodulatory characteristics of KSHV and related vIRFs.
April 29, 2017: Biological Chemistry
https://www.readbyqxmd.com/read/28451404/primary-cardiac-lymphoma-with-unusual-presentation-a-report-of-two-cases
#9
Chiu-Fan Chen, Pin-Pen Hsieh, Shyh-Jer Lin
Primary cardiac tumors are rare, with an incidence of 0.056% according to autopsy reports. The most common type is myxoma, while other types, including sarcoma, lipoma, papillary fibroelastoma, rhabdomyoma, fibroma, hemangioma, teratoma, lymphoma and mesothelioma also occur. Primary cardiac tumors usually cause embolization, pericardial effusion and arrhythmia, leading to heart failure. Only 10% of primary cardiac tumors are malignant, approximately 95% of which are sarcomas, while the remaining 5% are cardiac lymphomas and mesotheliomas...
March 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28430817/kaposi-sarcoma-herpesvirus-kshv-latency-associated-nuclear-antigen-lana-recruits-components-of-the-mrn-mre11-rad50-nbs1-repair-complex-to-modulate-an-innate-immune-signaling-pathway-and-viral-latency
#10
Giuseppe Mariggiò, Sandra Koch, Guigen Zhang, Magdalena Weidner-Glunde, Jessica Rückert, Semra Kati, Susann Santag, Thomas F Schulz
Kaposi Sarcoma Herpesvirus (KSHV), a γ2-herpesvirus and class 1 carcinogen, is responsible for at least three human malignancies: Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL) and Multicentric Castleman's Disease (MCD). Its major nuclear latency protein, LANA, is indispensable for the maintenance and replication of latent viral DNA in infected cells. Although LANA is mainly a nuclear protein, cytoplasmic isoforms of LANA exist and can act as antagonists of the cytoplasmic DNA sensor, cGAS. Here, we show that cytosolic LANA also recruits members of the MRN (Mre11-Rad50-NBS1) repair complex in the cytosol and thereby inhibits their recently reported role in the sensing of cytoplasmic DNA and activation of the NF-κB pathway...
April 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/28407694/molecular-mechanisms-of-activating-c-met-in-kshv-primary-effusion-lymphoma
#11
Bao Quoc Lam, Lu Dai, Li Li, Jing Qiao, Zhen Lin, Zhiqiang Qin
The oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) is a principal causative agent of primary effusion lymphoma (PEL), which is mostly seen in immunosuppressed patients. PEL is a rapidly progressing malignancy with a median survival time of approximately 6 months even under the conventional chemotherapy. We recently report that the hepatocyte growth factor (HGF)/c-MET pathway is highly activated in PEL cells and represents a promising therapeutic target (Blood. 2015;126(26):2821-31). However, the underlying mechanisms of c-MET activation within PEL cells remain largely unknown...
March 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28399009/primary-effusion-lymphoma-current-concepts-and-management
#12
Nivedita Arora, Arjun Gupta, Navid Sadeghi
PURPOSE OF REVIEW: To summarize the current epidemiology, management, and outcomes of primary effusion lymphoma (PEL) and highlight possible future research efforts. RECENT FINDINGS: Cyclophosphamide, doxorubicin, vincristine, prednisone-based chemotherapy regimens alone or in combination with immunomodulatory agents (e.g., lenalidomide), or proteasome inhibitors (e.g., bortezomib), or targeted therapies, are commonly used to treat PEL. Highly active antiretroviral therapy should be continued or initiated in patients with HIV infection...
April 8, 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/28396094/ym155-induces-apoptosis-through-proteasome-dependent-degradation-of-mcl-1-in-primary-effusion-lymphoma
#13
Yuki Kojima, Fumihiko Hayakawa, Takanobu Morishita, Keiki Sugimoto, Yuka Minamikawa, Mizuho Iwase, Hideyuki Yamamoto, Daiki Hirano, Naoto Imoto, Kazuyuki Shimada, Seiji Okada, Hitoshi Kiyoi
Primary effusion lymphoma (PEL) is a lymphoma that shows malignant effusion in body cavities without contiguous tumor masses and has a very poor prognosis. We recently developed a novel drug screening system using patient-derived xenograft (PDX) cells that maintained the primary cell phenotype better than cell lines. This screening is expected to discover anti-tumor drugs that have been overlooked by conventional screening using cell lines. We herein performed this screening to identify new therapeutic agents for PEL...
June 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28393364/sirt1-and-ampk-pathways-are-essential-for-the-proliferation-and-survival-of-primary-effusion-lymphoma-cells
#14
Meilan He, Brandon Tan, Karthik Vasan, Hongfeng Yuan, Fan Cheng, Suzane Ramos da Silva, Chun Lu, Shou-Jiang Gao
Primary effusion lymphoma (PEL) is a rare and aggressive B-cell lymphoma with a dismal prognosis caused by infection of Kaposi's sarcoma-associated herpesvirus. Despite the findings that numerous viral genes and cellular pathways are essential for the proliferation and survival of PEL cells, there is currently no effective therapeutic treatment for PEL. Here, we report that the metabolic sensor SIRT1 is functionally required for sustaining the proliferation and survival of PEL cells. Knockdown of SIRT1 with specific shRNAs or inhibition of SIRT1 with an inhibitor (Tenovin-6) induced cell cycle arrest and apoptosis in PEL cells...
April 9, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28383626/bilateral-hydrocele-uncommon-clinical-presentation-of-primary-testicular-lymphoma-in-the-elderly
#15
E Spaziani, A Di Filippo, P Francioni, F Fiorini, R Di Costanzo, V Ciaschi, M Spaziani, A De Cesare, M Picchio
Primary testicular lymphoma (PLT) represents 5% of testis tumors, the incidence increases in patients older than 60 years of age. Bilateral hydrocele is an unusual clinical presentation. Relapse in the central nervous system and in the contralateral testis is often observed. The US shows hypoechoic nodular lesions with a complete structural involvement of didymus and hypervascularization at Color Doppler. Orchiectomy should be performed in all cases as it is indispensable for the histopathological diagnosis and to characterize the immunophenotypic features...
March 2017: La Clinica Terapeutica
https://www.readbyqxmd.com/read/28376153/evidence-for-a-mesothelial-origin-of-body-cavity-effusion-lymphomas
#16
David Sanchez-Martin, Thomas S Uldrick, Hyeongil Kwak, Hidetaka Ohnuki, Mark N Polizzotto, Christina M Annunziata, Mark Raffeld, Kathleen M Wyvill, Karen Aleman, Victoria Wang, Vickie A Marshall, Denise Whitby, Robert Yarchoan, Giovanna Tosato
Background: Primary effusion lymphoma (PEL) is a Kaposi's sarcoma herpes virus (KSHV)-induced lymphoma that typically arises in body cavities of HIV-infected patients. PEL cells are often co-infected with Epstein-Barr virus (EBV). "PEL-like" lymphoma is a KSHV-unrelated lymphoma that arises in body cavities of HIV-negative patients. "PEL-like" lymphoma is sometimes EBV positive. The derivation of PEL/"PEL-like" cells is unclear. Methods: Mesothelial cells were cultured from body cavity effusions of 23 patients...
September 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28360465/diagnosis-and-management-options-in-malignant-pleural-effusions
#17
REVIEW
Ramakant Dixit, K C Agarwal, Archana Gokhroo, Chetan B Patil, Manoj Meena, Narender S Shah, Piyush Arora
Malignant pleural effusion (MPE) denotes an advanced malignant disease process. Most of the MPE are metastatic involvement of the pleura from primary malignancy at lung, breast, and other body sites apart from lymphomas. The diagnosis of MPE has been traditionally made on cytological examination of pleural fluid and/or histological examination of pleural biopsy tissue that still remains the initial approach in these cases. There has been tremendous advancement in the diagnosis of MPE now a day with techniques i...
March 2017: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/28336944/kaposi-s-sarcoma-associated-herpesvirus-orf34-is-essential-for-late-gene-expression-and-virus-production
#18
Mayu Nishimura, Tadashi Watanabe, Syota Yagi, Takahiro Yamanaka, Masahiro Fujimuro
Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. KSHV establishes a life-long infection in its host and alternates between a latent and lytic infection state. During lytic infection, lytic-related genes are expressed in a temporal manner and categorized as immediate early, early, and late gene transcripts. ORF34 is an early-late gene that interacts with several viral transcription-associated factors, however its physiological importance remains poorly understood...
March 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28321070/primary-malignant-lymphoma-originating-from-the-chest-wall-without-preceding-pleural-disease
#19
Yumi Iwasa, Asuka Okada, Hideaki Takenaka, Terukazu Takahashi, Nobuo Koguchi, Kumiko Katayama, Shinsuke Murakami, Sumito Choh, Koichi Tomoda, Hiroshi Kimura
An 84-year-old woman presented to our hospital with dyspnea on exertion and left back pain. Chest X-ray and chest computed tomography (CT) revealed an irregular pleural mass invading her left chest wall with rib destruction and pleural effusion. CT-guided needle biopsy revealed diffuse large B-cell lymphoma. Low-dose oral etoposide produced a complete response, and she continued oral chemotherapy for one year after the diagnosis and maintained good performance status. We herein report a very rare case of non-pyothorax-associated lymphoma that nonetheless resulted in great recovery...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28316327/obstructive-primary-cardiac-t-cell-lymphoma-a-case-report-from-senegal
#20
Simon Antoine Sarr, Abdou Majib Gaye, Fatou Aw, Jean de Dieu Nzambaza, Malick Bodian, Kana Babaka, Mouhamadou Bamba Ndiaye, Adama Kane, Maboury Diao, Serigne Abdou Ba
BACKGROUND Cardiac lymphoma is a rare entity, defined by the non-extra cardiac location at diagnosis. CASE REPORT Our patient was a 32-year-old female with no particular medical history, who presented with right heart failure with recurrent ascites and pleural effusion. There was a progressive worsening exertional dyspnea. On admission, examination revealed an irregular tachycardia at 170 beats per minute (bpm) and congestive heart failure. The electrocardiogram scored full tachyarrhythmia by atrial fibrillation with an average ventricular rate of 179 cycles per minute...
March 20, 2017: American Journal of Case Reports
keyword
keyword
62893
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"